ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Awards STRAP Grant Of $2 Million To MSKCC

October 22, 2010

NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.

April 20, 2007

“Mini-Transplantation” In Testing For Treatment Of Multiple Myeloma

January 25, 2002

New research Suggested For Immunobiology

November 18, 1977

NCI Bioinformatics After Kenneth Buetow: Varmus Launches Fundamental Redesign

January 6, 2012

Tumor Treating Fields Therapy Increased Three-Year Survival

November 25, 2011